Web17 gen 2024 · The most recent insider tranaction occured on January, 17th when SVP Arvin Yang sold 2,209 shares worth more than $12,679.66. Insiders at Mersana Therapeutics own 4.4% of the company. Information on this page was last updated on 1/17/2024. Timothy B. Lowinger Insider Trading History at Mersana Therapeutics See Full Table WebMersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the grant of an inducement award to the newly appointed Senior Vice President and Chief Medical …
Arvin Yang Net Worth (2024) Mersana Therapeutics, Inc Insider …
Web30 nov 2024 · CAMBRIDGE, Mass., Nov. 30, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq: MRSN), a clinical-stage biopharmaceutical company … Web3 mar 2024 · Mersana Therapeutics, Inc. (NASDAQ: MRSN) Q4 2024 Earnings Call Transcript February 28, 2024 Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024... dog breeds banned in germany 2019
Arvin Yang - Chief Medical Officer - Mersana Therapeutics - LinkedIn
Web21 feb 2024 · MERSANA THERAPEUTICS, INC.: prezzi di Borsa, grafici, quotazioni, consigli di Borsa, dati finanziari, analisi e notizie in tempo reale dell'azione MERSANA … Web13 mar 2024 · Mersana said the cause of the death, known as a Grade 5 serious adverse event, remains under investigation. Mersana said the patient who died was the second patient enrolled at the initial dose level in the dose-escalation portion of the Phase 1 study in previously treated patients with HER2+ recurrent or metastatic solid tumors. dog breeds banned in washington state